Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase-I Clinical Study to Evaluate the Safety, Pharmacokinetics and Anti-Tumor Activity of NRC-AN-019 in Patients with Solid Tumors.

Next Previous
X
Search
Trial Profile

A Phase-I Clinical Study to Evaluate the Safety, Pharmacokinetics and Anti-Tumor Activity of NRC-AN-019 in Patients with Solid Tumors.

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 21 Jan 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NRC AN 019 (Primary)
  • Indications Advanced breast cancer; Glioma; Non-small cell lung cancer; Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Natco Pharma

    • Most Recent Events

    • 10 Jan 2020 Status changed from recruiting to discontinued.
    • 13 Feb 2010 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top